Last updated: 11/03/2018 15:32:34
This product has been transferred to Novartis. GSK Clinical Study Register is no longer maintained for this study. The most up to date information is available on clinicaltrials.gov.
Study to investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
No longer a GSK study
No longer a GSK study
Trial overview
Official title: An Open-label mass balance study to investigate the Absorption, Distribution, Metabolism and Elimination of a Single Oral Dose of MEK inhibitor [14C]GSK1120212 in Male Subjects with Solid Tumors
Trial description: GSK1120212 is a reversible and highly selective allosteric inhibitor of MEK1 and MEK2 activation and kinase activity currently being developed for the treatment of malignant melanoma. This is a Phase I, open-label, non-randomized, single-dose study designed to characterize the absorption, distribution, metabolism, and elimination (ADME) of a single oral dose of MEK inhibitor [14C]GSK1120212 as a solution in male subjects with solid tumor malignancies. A sufficient number of subjects will be enrolled to complete approximately four evaluable subjects. Following completion of the study, subjects may elect to continue dosing with GSK1120212 in the rollover study, MEK114375.
Primary purpose:
Treatment
Trial design:
Single Group Assignment
Masking:
None (Open Label)
Allocation:
Non-randomized
Primary outcomes:
Total excretion of radioactivity
Timeframe: 11 days
Secondary outcomes:
Total radioactivity concentration in blood and plasma
Timeframe: 11 days
Characterize and quantify metabolites in urine plasma and feces
Timeframe: 11 days
Assess covalent binding of drug related material to plasma proteins
Timeframe: 11 days
Blood:plasma ratio
Timeframe: 11 days
Pharmacokentic concentrations in plasma
Timeframe: 11 days
AEs
Timeframe: From dosing on Day 1 to Follow-up
Vital signs
Timeframe: Screening, Day -1, Day 1, Day 5, and Follow-up
ECGs
Timeframe: Screening, Day 1 pre-dose, 24 hours, Day 11 and Follow-up
Clinical Laboratory assessments
Timeframe: Screening, Day -1, and Day 11
Interventions:
Drug: GSK1120212
Enrollment:
6
Observational study model:
Not applicable
Primary completion date:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Allen LF, Sebolt-Leopold J, Meyer MB. CI-140 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Seminars in Oncology. 2003;30:105-166.
Davies H, Bignell, GR, Cox, C, Stephens, P, Edkins, S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
GlaxoSmithKline Document Number HM2009/00151/01 GSK1120212 Investigator's Brochure Report Date 4 June 2010.
GlaxoSmithKline Document Number RD2009/01379/00. Dosimetry Review for oral [14C]GSK1120212. Report Date 19-Nov-2009.
GlaxoSmithKline Document Number RM2007/00642/03. MEK111054: An open-label, multiple-dose, dose escalation study to investigate the safety, harmacokinetics, and pharmacodynamics of the MEK inhibitor GSK1120212 in subjects with solid tumors or lymphoma. 2009.
LoRusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. Journal of Clinical Oncology. 2005;23:5281-93.
LoRusso PM, Krishnamurthi S, Rinehart JR, et al. A Phase 1-2 clinical study of the second-generation MEK inhibitor, PD 0325901 in patients with advanced cancer. J Clin Oncol. 2005; 23:3011.
LoRusso PM, Krishnamurthi SS, Rinehart JJ, Nabell LM, Croghan GA, Chapman PB, Selaru P, Kim S, Ricart AD, Wilner KD. Clinical aspects of a phase I study of PD-0325901, a selective oral MEK inhibitor, in patients with advanced cancer. Presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2007; 6:3649s [abstr B113].
NCI. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. DHHS,NCI, NIH, Bethesda, MD; 2009.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and Response Criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology. 1982;5:649-655.
Tzekova, V, Cebotaru C, Ciuleanu TE, et al. Efficacy and safety of AZD6244 (ARRY-142886) as second/third-line treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2008; 26:431s.
May Y K Ho, Michael J Morris, Jill L Pirhalla, John W Bauman, Carolyn B Pendry, Keith W Orford, Royce A Morrison, Donna S Cox.Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers.Xenobiotica.2014;44(4):352-368
Medical condition
Cancer
Product
trametinib
Collaborators
Not applicable
Study date(s)
February 2011 to July 2011
Type
Interventional
Phase
1
Participation criteria
Sex
Male
Age
18+ years
Accepts healthy volunteers
No
- 1. Male 18 years old or older.
- 2. Written informed consent provided
- 1. Currently receiving cancer therapy as specified in the protocol.
- 2. Serious and/or unstable pre-existing medical psychiatric disorder, or other conditions.
Inclusion and exclusion criteria
Inclusion criteria:
- 1. Male 18 years old or older. 2. Written informed consent provided 3. Body weight greater than or equal to 45 kg and a BMI greater than or equal to 19 kg/m2 and less than or equal to 35 kg/m2 (inclusive). 4. Able to swallow and retain oral medication. 5. Histologically or cytologically confirmed diagnosis of a solid tumor. 6. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. 7. Agree to use one of the contraception methods listed in the protocol from the time of the first dose of study medication until sixteen weeks after the last dose of study medication. 8. A history of regular bowel movements (approximately once per day). 9. Adequate baseline organ function as listed in the protocol.
Exclusion criteria:
- Use of anticoagulants such as warfarin is permitted. 10. History RVO or CSR.
- Predisposing factors to RVO or CSR.
- Visible retinal pathology that is considered a risk factor for RVO or CSR such as:
- Evidence of new optic disc cupping
- Intraocular pressure greater than 21 mm Hg as measured by tonography. 11.1. Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression. (Previously treated and have had stable CNS disease for greater than 3 months, asymptomatic and off corticosteroids, or on stable dose of corticosteroids for at least 1 month prior to study Day 1 are permitted). 11.2. Receiving enzyme inducing anti-epileptic drugs (EIAEDs). 12. History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within the past 6 months. 13. QTcB greater than or equal to 480 msec. 14. History or evidence of current clinically significant uncontrolled arrhythmias. 15. History or evidence of current greater than or equal to Class II congestive heart failure. 16. Active gastrointestinal disease or other condition (e.g., gastrectomy, bariatric surgery, small bowel or large bowel resection, or cholecystectomy). 17. A history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus, or Hepatitis C Virus. 18. Alcohol or drug abuse within six months prior to screening. 19. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study drugs or excipients. 20. Participated in a clinical trial and has received an investigational product within 30 days or five half-lives or twice the duration of the biological effect of the investigational product (whichever is longer) before the 1st dose. 21. Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period. 22. Mentally or legally incapacitated.
1. Currently receiving cancer therapy as specified in the protocol. 2. Serious and/or unstable pre-existing medical psychiatric disorder, or other conditions. 3. Any major surgery within the last four weeks. 4. Unresolved toxicity equal to or greater than Grade 2 from previous anti-cancer therapy except alopecia. 5. An occupation within the past 12 months which requires monitoring for radiation exposure, nuclear medicine procedures or excessive x-rays. 6. Radiation exposure from the previous three year period over 10 mSv if exposed to ionizing radiation above background as a result of work with radiation as category A (classified) workers or as a result of research studies. 7. History of interstitial lung disease or pneumonitis. 8. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to dimethyl sulfoxide (DMSO). 9. Current use of a prohibited medications described in the protocol.
Trial location(s)
Location
GSK Investigational Site
Tacoma, Washington, United States, 98418
Status
Study Complete
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
No longer a GSK study
Actual primary completion date
Not applicable
Actual study completion date
2011-18-07
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Results for study 113708 can be found on the GSK Clinical Study Register.
Click hereAccess to clinical trial data by researchers
Visit website